The nonprofit foundation founded by philanthropist and billionaire Tony Barnes is making a $100 million investment in a new cancer drug that could one day treat depression in women.
The investment by the Barnes Foundation is the largest ever in a pharmaceutical development program, according to the foundation.
It is the first time that a cancer drug has been funded by the foundation and is also a big step in a promising field of research, said Deborah Blum, director of the foundation’s Breast Cancer Research Center.
“This is a major step forward,” Blum said in a statement.
“We are very excited to see the future of the Barnet Foundation as it prepares to deliver the best-in-class cancer drug to women across the globe.”
The new drug, a biologic compound called C-SPAN3, is one of several promising new therapies in cancer treatments.
The drug is designed to be able to penetrate the cells of cancerous tumors, which can cause debilitating pain, nausea and other physical symptoms.
It also works to relieve symptoms of chronic inflammation in the body, such as arthritis, and reduces inflammation in tumors that have been resistant to other treatments.
In an interview with The Associated Press, Barnes said the drug has “a lot of potential” for women.
The pharmaceutical company said the development of C-span3 was a partnership between Barnes and the foundation, with the goal of providing cancer treatment to more women than ever before.
The company also said it is the only pharmaceutical company in the world working to develop a new class of cancer drugs.
The drug has already shown promising results in animal studies.
In addition to helping women with cancer, the drug also works as an adjuvant for other drugs and vaccines, such the one for a deadly form of brain cancer called Duchenne muscular dystrophy.
The first human trials of the drug, which began in January, are expected to begin later this year.
The foundation’s plan also calls for the company to work with other cancer-related groups and government agencies to create a database that can track the progress of cancer treatments and the drug’s safety.
The goal is to help the foundation track and track drug development and distribution, Blum told the AP.
The pharmaceutical company announced in December that it was launching an ambitious plan to create an online database to track drug distribution.
The news of the new drug’s potential impact comes on the heels of an announcement from the American Cancer Society that it is working with the Barnets to create information about how to treat cancer in women with chronic inflammation.
The ACS said that a new clinical trial of the drugs is set to begin in the second quarter.